Press Releases – Enthera

Enthera Pharmaceuticals Appoints Claudia Nardini as Vice President of Research and Development

1st April 2021/in Press Releases /by hearten

Milan, Italy, 1 April 2021 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing novel disease-modifying biologics that re-establish stem cell capabilities to treat specific autoimmune diseases, today announces the appointment of Claudia Nardini as Vice President of Research and Development to support the Company’s manufacturing and regulatory divisions. Claudia has 25 years of experience in […]

Enthera Pharmaceuticals extends Series A financing, raising a total of €35 million

28th January 2021/in Press Releases /by hearten

The Roche Venture Fund joins international investor syndicate, including co-lead investors Sofinnova Partners and AbbVie Ventures Funds to be used to advance restorative therapy for type 1 diabetes and inflammatory bowel disease Largest international VC-backed Series A financing round for a biotech in Italy to date and first ever venture investment in an Italian company […]

Enthera Pharmaceuticals appoints Kazumi Shiosaki to its Board of Directors and Lisa Olson to its Scientific Advisory Board to push forward company growth and development

3rd December 2020/in Press Releases /by hearten

Milan, Italy, 3 December 2020 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, announces that it has appointed Kazumi Shiosaki to its Board of Directors, and Lisa Olson to its Scientific Advisory Board.

Enthera Pharmaceuticals raises €28 million in Series A financing to advance restorative therapy for type 1 diabetes and inflammatory bowel disease

28th July 2020/in Press Releases /by hearten

Milan, Italy – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announces the completion of a €28 million Series A financing round.

Enthera, the first spin-off of BiovelocITA, completed €4 million seed-expansion financing

24th July 2018/in Press Releases /by hearten

Enthera, an innovative Italian start-up dedicated to the research and development of innovative therapeutics to treat Type 1 Diabetes and gastrointestinal diseases, received an investment of €4 million led by Sofinnova along with the JDRF T1D Fund (the venture capital fund of the authoritative US JDRF Foundation dedicated to promoting research on Type 1 Diabetes), the accelerator BiovelocITA and its shareholders.

Enthera and Trianni Announce Licensing Agreement

22nd March 2018/in Press Releases /by hearten

Trianni, Inc. (“TRIANNI”) and Enthera, S.r.L. (“ENTHERA”) jointly announced today that ENTHERA has entered into a license agreement for The Trianni Mouse™, a best-in-class monoclonal antibody discovery platform.

BiovelocITA, the Italian biotech accelerator, launches two companies, one against diabetes, the other against cancer

23rd November 2016/in Press Releases /by hearten

Two research project collaborations – one in diabetes and one in oncology – have been launched, with a total investment of €2.5 million. These are the first projects launched by BiovelocITA, the Italian biotech accelerator launched last year by the chemist and entrepreneur Silvano Spinelli, Gabriella Camboni and the venture capital firm Sofinnova Partners.